GlobalData says that the industry has “absorbed significant disruption”, with high M&A levels testament to recovery.
Amidst regulatory turmoil and a funding resurgence, companies provide insights on how they are navigating the changing industry.
uniQure confirmed it will submit its BLA in Q3 2026, though there is still a required confirmatory study to conduct.
The proposed acquisition will add anti-inflammatory candidates to Biogen, including RayThera’s lead asset.
The new arrangement between Voro and Alloy centres on finding approaches that may enhance the therapeutic index of TCE therapies.
AbCellera will conduct discovery and early-stage research activities on two initial programmes.
